BRPI0711608B8 - composição liofilizada, uso de antígeno viral, método de tratamento ou prevenção de vírus associado, método de adaptação de um vírus de uma linhagem celular adequada - Google Patents

composição liofilizada, uso de antígeno viral, método de tratamento ou prevenção de vírus associado, método de adaptação de um vírus de uma linhagem celular adequada

Info

Publication number
BRPI0711608B8
BRPI0711608B8 BRPI0711608A BRPI0711608A BRPI0711608B8 BR PI0711608 B8 BRPI0711608 B8 BR PI0711608B8 BR PI0711608 A BRPI0711608 A BR PI0711608A BR PI0711608 A BRPI0711608 A BR PI0711608A BR PI0711608 B8 BRPI0711608 B8 BR PI0711608B8
Authority
BR
Brazil
Prior art keywords
virus
viral antigen
composition
adapting
protein
Prior art date
Application number
BRPI0711608A
Other languages
English (en)
Inventor
Mohan Vadrevu Krishna
Murthy Ella Krishna
Singhania Smita
Jerusha Augustus Harshavardhan Gutla Victor
Original Assignee
Bharat Biotech Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Biotech Int Ltd filed Critical Bharat Biotech Int Ltd
Publication of BRPI0711608A2 publication Critical patent/BRPI0711608A2/pt
Publication of BRPI0711608B1 publication Critical patent/BRPI0711608B1/pt
Publication of BRPI0711608B8 publication Critical patent/BRPI0711608B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

composição liofilizada, uso de antígeno viral, método de tratamento ou prevenção de vírus associado, método de adaptação de um vírus de uma linhagem celular adequada. a presente invenção refere-se a uma composição compreendendo um antígeno viral, uma primeira proteína e uma segunda proteína. opcionalmente, a composição igualmente compreende três dissacarídeos diferentes, ou, opcionalmente, a composição compreende um açúcar primário e pelo menos um, preferivelmente dois açúcares secundários. a presente invenção igualmente refere-se ao uso de um antígeno viral, de uma primeira proteína e de uma segunda proteína para a fabricação de uma composição, preferivelmente uma vacina. a presente invenção, além disso, refere-se a um método de tratamento ou prevenção do vírus associado a doenças nos humanos. além disso, a presente invenção refere-se a um método de adaptar um vírus a uma linhagem celular apropriada. a invenção é igualmente útil para a produção de suspensões de vírus apropriadas para fazer composições de vacinais de rotavírus estáveis, vivas/inativadas, monovalentes e/ou polivalentes, líquidas/liofilizadas para meio de administração oral e/ou nasal ou qualquer outro meio apropriado em humano.
BRPI0711608A 2006-05-12 2007-05-11 composição liofilizada, uso de antígeno viral, método de tratamento ou prevenção de vírus associado, método de adaptação de um vírus de uma linhagem celular adequada BRPI0711608B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN842/CHE/2006 2006-05-12
IN842CH2006 2006-05-12
PCT/IN2007/000190 WO2007132480A2 (en) 2006-05-12 2007-05-11 A composition useful as a vaccine

Publications (3)

Publication Number Publication Date
BRPI0711608A2 BRPI0711608A2 (pt) 2012-08-14
BRPI0711608B1 BRPI0711608B1 (pt) 2019-08-20
BRPI0711608B8 true BRPI0711608B8 (pt) 2021-05-25

Family

ID=38578478

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0711608A BRPI0711608B8 (pt) 2006-05-12 2007-05-11 composição liofilizada, uso de antígeno viral, método de tratamento ou prevenção de vírus associado, método de adaptação de um vírus de uma linhagem celular adequada

Country Status (8)

Country Link
US (1) US9642907B2 (pt)
CN (1) CN101489587B (pt)
AU (1) AU2007251122B2 (pt)
BR (1) BRPI0711608B8 (pt)
GB (1) GB2451216B (pt)
MX (1) MX2008014391A (pt)
WO (1) WO2007132480A2 (pt)
ZA (1) ZA200809622B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012000588A2 (pt) * 2009-07-13 2020-08-11 Bharat Biotech International Limited composição, composição líquida, composição liofilizada e método para produzir um rotavirus atenuado
RU2013136397A (ru) * 2011-01-05 2015-02-10 Бхарат Байотек Интернэшнл Лимитед Комбинированная семивалентная вакцина
WO2013105105A2 (en) * 2012-01-13 2013-07-18 Serum Institute Of India Ltd. Novel viral vaccine compositions and methods for preparing such vaccines
BR112014026407B1 (pt) 2012-04-23 2020-12-22 Bharat Biotech International Limited formulação de vacina líquida
CN104812892B (zh) * 2012-08-27 2018-07-17 默多克儿童研究所 经修饰的人轮状病毒及其用途
US9480739B2 (en) * 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
AR097762A1 (es) * 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
EP3053594A4 (en) * 2013-10-03 2017-05-10 Nitto Denko Corporation Dried influenza vaccine preparation and method for producing dried influenza vaccine preparation
US10532093B2 (en) * 2014-07-18 2020-01-14 Mds Wellcome Trust Hilleman Laboratories Pvt. Ltd. Thermostable freeze dried rotavirus vaccine formulation and process to prepare thereof
TWI745278B (zh) 2014-10-10 2021-11-11 以色列商艾畢克生物實驗有限公司 發泡性降低之疫苗組合物
US11123420B2 (en) * 2015-09-30 2021-09-21 Panacea Biotec Limited Stable live attenuated recombinant dengue vaccine
GB201608323D0 (en) * 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
MA44557B1 (fr) * 2016-06-16 2021-11-30 Bharat Biotech Int Ltd Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer
GB201614799D0 (en) * 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
US11110163B2 (en) 2017-02-14 2021-09-07 Inventprise, Llc Heat stable vaccines
WO2018152237A1 (en) 2017-02-14 2018-08-23 Inventprise, Llc Heat stable liquid rotavirus vaccine
CN108434106B (zh) * 2017-04-25 2021-07-30 广州瑞贝斯药业有限公司 一种狂犬病疫苗的冻干制剂
CN110055225A (zh) * 2018-01-18 2019-07-26 北京依生兴业科技有限公司 一种提高轮状病毒产量的方法
MX2021007639A (es) 2018-12-27 2021-08-11 Amgen Inc Formulaciones de virus liofilizadas.
CN113994925B (zh) * 2021-12-30 2022-04-26 北京赛尔富森生物科技有限公司 一种轮状病毒攻毒动物模型及其建立方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629399A (en) * 1967-09-05 1971-12-21 Behringwerke Ag Stable poliomyelitis vaccines
SE445466B (sv) * 1977-12-01 1986-06-23 Wellcome Found Sett att foroka rotavirus in vitro
ES2122973T3 (es) 1990-07-26 1999-01-01 Wistar Inst Vacuna de recombinante de rotavirus.
US5773009A (en) 1994-04-15 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services Rotavirus strain G9P11
WO1996001651A1 (en) 1994-07-11 1996-01-25 The Government Of The United States Of America, Represented By The Department Of Health And Human Services Attenuated human rotavirus vaccine
US6616931B1 (en) * 1996-09-26 2003-09-09 Merck & Co., Inc. Rotavirus vaccine formulations
US5932223A (en) * 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
US6290967B1 (en) 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
US6210683B1 (en) * 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
FR2791895B1 (fr) * 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
ES2327103T3 (es) * 2000-09-25 2009-10-26 Polymun Scientific Immunbiologische Forschung Gmbh Vacuna viva de influenzavirus y procedimiento de fabricacion.
BRPI0417672A (pt) 2003-12-17 2007-03-20 Wyeth Corp processos para produzir composições de vìrus estáveis em armazenamento, composições de vìrus e imunogênicas
CA2587849A1 (en) * 2004-11-19 2006-05-26 Intervet International B.V. Porcine reproductive and respiratory syndrome virus strains and compositions
GB0503337D0 (en) * 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
ATE523207T1 (de) * 2005-09-16 2011-09-15 Merial Ltd Stabilisatoren für gefriergetrocknete impfstoffe
US20090035326A1 (en) * 2005-11-01 2009-02-05 Novartis Ag Compositions with antigens adsorbed to calcium phosphate

Also Published As

Publication number Publication date
ZA200809622B (en) 2009-07-29
GB0821386D0 (en) 2008-12-31
WO2007132480A3 (en) 2008-03-20
BRPI0711608A2 (pt) 2012-08-14
MX2008014391A (es) 2009-03-06
AU2007251122A1 (en) 2007-11-22
US9642907B2 (en) 2017-05-09
BRPI0711608B1 (pt) 2019-08-20
CN101489587B (zh) 2015-05-27
WO2007132480B1 (en) 2008-05-22
CN101489587A (zh) 2009-07-22
WO2007132480A2 (en) 2007-11-22
US20100068227A1 (en) 2010-03-18
AU2007251122B2 (en) 2013-01-10
GB2451216A (en) 2009-01-21
GB2451216B (en) 2011-05-04

Similar Documents

Publication Publication Date Title
GB2451216A (en) A composition useful as a vaccine
BR112012022669A2 (pt) composição imunogênica, método de tratamento ou prevenção de infecção ou doença, uso de um antígeno, kit, métodos para a fabricação de uma composição imunogênica e para melhorar uma vacina.
EA201490512A1 (ru) Композиции, содержащие культивируемую в анаэробных условиях микробиоту кишечника человека
BR112015019066A2 (pt) Anticorpos humanos para proteína f do vírus respiratório sincicial e métodos de uso dos mesmos
BRPI0720667A8 (pt) Métodos de administração de vacina
AR080685A1 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
MX391339B (es) Composicion farmaceutica que comprende selexipag.
BR112014006220A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
DE602007013618D1 (de) Antikörper gegen das humane cytomegalie-virus (hcmv)
EA200701519A1 (ru) Живая аттенуированная ротавирусная вакцина для перорального введения
BR112014004860A2 (pt) composições de anticorpo contra vírus da influenza
BRPI0809663A8 (pt) Composição de vírus vivo atenuado, usos da mesma, métodos de diminuição da inativação de vírus vivo atenuado, e kit para diminuir a inativação de uma composição de vírus vivo atenuado.
NO20083793L (no) Antistoffer mot amyloid-beta peptid
EA201290131A1 (ru) Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
ATE295180T1 (de) Zubereitung zur immunisierung gegen den aids- virus
BR112012004806B8 (pt) composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
BRPI0707543B8 (pt) composição de polipeptídeo e uso da mesma
BR112014028633A8 (pt) tratamento de amd usando sflt-1 de aav
BRPI0511776A (pt) vìrus atenuado de influenza de suìnos, formulação imunogênica, formulação farmacêutica, métodos para imunizar ou induzir uma resposta imune em um porco, para tratar uma infecção por vìrus de influenza de suìnos em um porco, para tratar cáncer em um porco, e para produzir uma formulação imunogênica, célula, linhagem de células de porco, e, ovo embrionado
MX2018013782A (es) Antigenos y vacunas dirigidos contra enterovirus humanos.
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
BR112022000710A2 (pt) Vacina viral terapêutica
MY157661A (en) Bendamustine pharmaceutical compositions
PH12013501373B1 (en) Bovine viral diarrhea virus type 1b vaccine compositions and methods
BR112014002860A2 (pt) vacinas de pasteurellaceae

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE A PROCURACAO APRESENTADA NAO POSSUI DATA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B65X Notification of requirement for priority examination of patent application
B65Z Priority examination of the patent application refused (request does not comply with dec. 132/06 of 20061117)
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/08/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/08/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/05/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.